NDAOPHTHALMICSOLUTION/DROPS
Approved
Aug 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
ALPHAGAN P (brimonidine tartrate) by AbbVie is alpha-2 adrenergic receptor agonist with a peak ocular hypotensive effect occurring at two hours post-dosing. Approved for ocular hypertension, glaucoma. First approved in 2005.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALPHAGAN P is an ophthalmic solution containing brimonidine tartrate, an alpha-2 adrenergic receptor agonist approved by the FDA in August 2005. It is indicated for the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. The drug works through a dual mechanism: reducing aqueous humor production and increasing uveoscleral outflow, with peak IOP-lowering effects occurring approximately two hours after administration. ALPHAGAN P is a standard-of-care adjunctive or monotherapy agent in the glaucoma treatment landscape.
$0.2BPart D
Mechanism of Action
alpha-2 adrenergic receptor agonist with a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow.
Indications (2)
Worked on ALPHAGAN P at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.